AIREX: Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

タイトル	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
DOI	https://doi.org/10.1038/s41598-021-04075-0
本文（外部サイト）	https://ir.library.osaka-u.ac.jp/repo/ouka/all/93206/SciRep_12_1.pdf
著者（英）	Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi; Yamamoto, Wataru; Hashimoto, Motomu; Murata, Koichi; Onishi, Akira; Jinno, Sadao; Hara, Ryota; Son, Yonsu; Amuro, Hideki; Takeuchi, Tohru; Yoshikawa, Ayaka; Katayama, Masaki; Yamamoto, Keiichi; Okita, Yasutaka; Hirao, Makoto; Etani, Yuki; Kumanogoh, Atsushi; Okada, Seiji; Nakata, Ken
発行日	2022-01-07
発行機関など	Nature Research
刊行物名	Scientific Reports
巻	12
号	1
開始ページ	134
言語	eng
内容記述	Ebina K., Hirano T., Maeda Y., et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Scientific Reports 12, 134 (2022); https://doi.org/10.1038/s41598-021-04075-0. This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with either BAR (n = 166) or TOF (n = 185); bDMARDs- or JAKi-switched cases (76.6%). The reasons for drug discontinuation were classified into four major categories. The drug retention was evaluated at 24 months using the Kaplan–Meier method and multivariate Cox proportional hazards modelling adjusted by confounders. Discontinuation rates for the corresponding reasons were as follows; ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%) and remission (0.0%). Prior history of anti-interleukin-6 receptor antibody (aIL-6R) ineffectiveness significantly increased the risk of treatment discontinuation due to ineffectiveness (p = 0.020). Aging (≥ 75 years) (p = 0.028), usage of PSL ≥ 5 mg/day (p = 0.017) and female sex (p = 0.041) significantly increased the risk of treatment discontinuation due to toxic adverse events. Factors not associated with treatment discontinuation were: number of prior bDMARDs or JAKi, concomitant MTX usage, difference of JAKi, and prior use of TNF inhibitor, CTLA4-Ig or other JAKi.
権利	This article is licensed under a Creative Commons Attribution 4.0 International License.
URI	https://repository.exst.jaxa.jp/dspace/handle/a-is/1235202